{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:24:07Z","timestamp":1772079847180,"version":"3.50.1"},"reference-count":94,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Ophthalmic diseases include both those analogous to systemic diseases (eg, inflammation, infection, neuronal degeneration) and not analogous (eg, cataract, myopia). Many anterior segment diseases are treated pharmacologically through eye drops, which have an implied therapeutic index of local therapy. Unlike oral dosage forms administered for systemic diseases, eyedrops require patients not only to adhere to treatment, but to be able to accurately perform\u2014ie, instill drops correctly.<\/jats:p><jats:p>Anatomical and physiological barriers make topical delivery to the anterior chamber challenging\u2014in some cases more challenging than absorption through the skin, nasal passages, or gut. Treatment of the posterior segment (eg, vitreous, retina, choroid, and optic nerve) is more challenging due to additional barriers. Recently, intravitreal injections have become a standard of care with biologics for the treatment of macular degeneration and other diseases. Although the eye has esterases, hydroxylases, and transporters, it has relatively little CYP450 enzymes. Because it is challenging to obtain drug concentrations at the target site, ocular clinical pharmacokinetics, and thus pharmacokinetic\u2010pharmacodynamic interactions, are rarely available. Ophthalmic pharmaceuticals require consideration of solubility, physiological pH, and osmolarity, as well as sterility and stability, which in turn requires optimal pharmaceutics. Although applied locally, ocular medications may be absorbed systemically, which results in morbidity and mortality (eg, systemic hypotension, bronchospasm, and bradycardia).<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.634","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T09:48:50Z","timestamp":1441964930000},"page":"517-527","source":"Crossref","is-referenced-by-count":39,"title":["Ocular pharmacology"],"prefix":"10.1002","volume":"56","author":[{"given":"Gary D.","family":"Novack","sequence":"first","affiliation":[{"name":"PharmaLogic Development, Inc. San Rafael CA USA"},{"name":"Departments of Pharmacology and Ophthalmology University of California Davis CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L.","family":"Robin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Maryland Baltimore MD USA"},{"name":"Department of Ophthalmology University of Michigan Ann Arbor MI USA"},{"name":"Department of Ophthalmology Johns Hopkins University Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"e_1_2_15_2_1","unstructured":"Goss CM.The Organs of the Senses 29th ed. Philadelphia: Lea & Febiger 1973."},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.297"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011711-113247"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.96"},{"key":"e_1_2_15_6_1","unstructured":"EdmanP.Biopharmaceutics of Ocular Drug Delivery (Pharmacology and Toxicology). Boca Raton FL: CRC Press; 1993."},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.001"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"e_1_2_15_9_1","unstructured":"BrownRH NovackGD.General principles of ophthalmic medications. In: Morrison J Pollack I eds.Glaucoma: Science and Practice. New York: Thieme Publishing Company 2002;354\u2013362."},{"key":"e_1_2_15_10_1","first-page":"1849","article-title":"Systemic medications and glaucoma patients (letter)","volume":"112","author":"Covert D","year":"2005","journal-title":"Ophthalmology"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021121"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4290"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(80)35215-9"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100010079024"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1224"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70063-0"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.007"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2014.11.002"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00899-5"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2007.02.032"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2012.07.031"},{"key":"e_1_2_15_22_1","doi-asserted-by":"crossref","unstructured":"PackerM ChangDF DeweySH et al. Prevention diagnosis and management of acute postoperative bacterial endophthalmitis.J Cataract Refract Surg.2011;37:1699\u20131714.","DOI":"10.1016\/j.jcrs.2011.06.018"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1992.01080230055019"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.11.1493"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090240037023"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707103370203"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01327-2"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70076-9"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997a"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70082-4"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2012.02.001"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70085-X"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2014.05.001"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.532"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.05.030"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9469"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32832401a9"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72725-4"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00873-9"},{"key":"e_1_2_15_43_1","unstructured":"PanelAAO.Preferred Practice Pattern: Primary Open\u2010Angle Glaucoma. San Francisco CA: American Academy of Ophthalmology; 2010.http:\/\/www.aao.org\/preferred\u2010practice\u2010pattern\/primary\u2010openangle\u2010glaucoma\u2010ppp\u2010\u2010october\u20102010."},{"key":"e_1_2_15_44_1","unstructured":"PanelAAO.Preferred Practice Pattern: Primary Open\u2010Angle Glaucoma Suspect. San Francisco CA: American Academy of Ophthalmology; 2010.http:\/\/www.aao.org\/preferred\u2010practice\u2010pattern\/primary\u2010openangle\u2010glaucoma\u2010suspect\u2010ppp\u2010\u2010october\u201020."},{"key":"e_1_2_15_45_1","unstructured":"SocietyEG.Terminology and Guidelines for Glaucoma 4th ed. Savona Italy: PubliComm; 2014."},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.66"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.026"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.07.016"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160139001"},{"key":"e_1_2_15_50_1","article-title":"Out\u2010flow pressure, minute volume and resistance of the anterior chamber flow in man","author":"Goldmann H.","year":"1951","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2003.07.002"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.022"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0146"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3182952213"},{"key":"e_1_2_15_55_1","doi-asserted-by":"crossref","unstructured":"WilliamsRD NovackGD van HaarlemT KopczynskiC;AR\u201012286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR\u201312286 in patients with glaucoma and ocular hypertension.Am J Ophthalmol. 2011;152:834\u2013841.e1.","DOI":"10.1016\/j.ajo.2011.04.012"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.016"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.76"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(93)31484-3"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00306-5"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1981.03930020086007"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1978.03910060433007"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100080061030"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199808000-00007"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)75247-X"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(88)33038-1"},{"key":"e_1_2_15_66_1","first-page":"729","article-title":"The role of apraclonidine hydrochloride in laser therapy for glaucoma","volume":"87","author":"Robin AL.","year":"1989","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100120044006"},{"key":"e_1_2_15_68_1","article-title":"Medicinal cannabis for glaucoma","author":"Novack GD.","journal-title":"Curr Opin Ophthalmol"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.06.012"},{"key":"e_1_2_15_70_1","first-page":"63","volume":"3","author":"Novack GD","year":"2005","journal-title":"Ocul Surf"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01637506"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2012.12.001"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1978.03910050250011"},{"key":"e_1_2_15_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1971.01000010140004"},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.2610040402"},{"key":"e_1_2_15_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70141-6"},{"key":"e_1_2_15_77_1","unstructured":"Cannan RK.The Drug Efficacy Study of the National Research Council's Division of Medical Sciences 1966\u20101969 1968. Washington DC: National Academy of Sciences.http:\/\/www.nasonline.org\/about\u2010nas\/history\/archives\/collections\/des\u20101966\u20101969\u20101.html?referrer=https:\/\/www.google.com\/."},{"key":"e_1_2_15_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00466-8"},{"key":"e_1_2_15_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.339"},{"key":"e_1_2_15_80_1","first-page":"919","article-title":"Clinical trial of flurbiprofen to maintain pupillary dilation during cataract surgery","volume":"16","author":"Keates RH","year":"1984","journal-title":"Ann Ophthalmol"},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74268-0"},{"key":"e_1_2_15_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(90)32423-5"},{"key":"e_1_2_15_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004397-199303340-00012"},{"key":"e_1_2_15_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414221"},{"key":"e_1_2_15_85_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017293"},{"key":"e_1_2_15_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.045"},{"key":"e_1_2_15_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.10.1417"},{"key":"e_1_2_15_88_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.10.1329"},{"key":"e_1_2_15_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.4154"},{"key":"e_1_2_15_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(80)35127-0"},{"key":"e_1_2_15_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1984.01040031184014"},{"key":"e_1_2_15_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.09.020"},{"key":"e_1_2_15_93_1","doi-asserted-by":"crossref","unstructured":"Siatkowski RM Cotter SA Crockett RS Miller JM Novack GD Zadnik K. Two\u2010year multicenter randomized double\u2010masked placebo\u2010controlled parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia.J AAPOS. 2008;12:332\u2013339.","DOI":"10.1016\/j.jaapos.2007.10.014"},{"key":"e_1_2_15_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.06.038"},{"key":"e_1_2_15_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.392"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.634","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:34:40Z","timestamp":1696512880000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/jcph.634"],"URL":"https:\/\/doi.org\/10.1002\/jcph.634","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}